omniture
logo
Search
RemeGen Co., Ltd
Media Room

Latest News

rss

RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China

YANTAI, China, Sept. 19, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995....

2022-09-19 21:00 2296

Biotech Company RemeGen Commemorates International Self-Care Day with Health Initiatives

YANTAI, China, July 25, 2022 /PRNewswire/ -- The 24th of July marks International Self Care Day, hi...

2022-07-25 11:00 2409

RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting

YANTAI, China, May 23, 2022  /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK, SHA: 688331), a commercial...

2022-05-24 10:27 2326

RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome

YANTAI, China, Jan. 26, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotec...

2022-01-26 10:52 3895

RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome

YANTAI, China, Jan. 24, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotec...

2022-01-25 09:00 3788

RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021

YANTAI, China, Dec. 15, 2021 /PRNewswire/ -- To celebrate World Strengthened Immunity Day, RemeGen ...

2021-12-15 09:35 3393

RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment

YANTAI, China, Dec. 3, 2021 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotech...

2021-12-03 13:45 5308
123